Patents Assigned to BIOAPPLICATIONS INC.
  • Patent number: 12721887
    Abstract: The present invention relates to a vaccine composition including, as active ingredients, a recombinant Zika virus envelope protein including an amino acid sequence of SEQ ID NO: 1, and an adjuvant selected from alum, monophosphoryl lipid A (MPL), or a combination thereof, a recombinant vector for producing the recombinant Zika virus envelope protein in a plant, a transformant transformed with the vector, and a method for producing the recombinant Zika virus envelope protein.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: September 1, 2026
    Assignees: BIOAPPLICATIONS INC., INNOVAC CORPORATION
    Inventors: Tae-Wook Hahn, Minna Shin, Eun-Ju Sohn, Hyangju Kang
  • Patent number: 12385056
    Abstract: The present invention relates to a method for mass-producing a target protein in a plant and, more specifically, to a method for producing high levels of protein in plant leaf cells, in which an expression cassette construct for high expression of a target gene and an expression cassette construct for high expression of p38 as a gene silencing suppressor, are prepared, a binary vector for transient expression in plant cells, having the construct together, is then prepared, and the binary vector is then subjected to agrobacterium-mediated transformation by using a single agrobacterium culture.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: August 12, 2025
    Assignees: POSTECH ACADEMY-INDUSTRY FOUNDATION, BioApplications Inc.
    Inventors: In Hwan Hwang, Hyang Ju Kang, Jun Ho Lee, Shijian Song, Selvan Thangarasu Muthamil
  • Patent number: 12357686
    Abstract: The present invention relates to: a porcine epidemic diarrhea (PED) virus protein comprising an amino acid sequence represented by SEQ ID NO:5; a vaccine composition comprising same; and the like.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: July 15, 2025
    Assignee: BIOAPPLICATIONS INC.
    Inventors: Eun-Ju Sohn, Yong Jik Lee
  • Patent number: 12357685
    Abstract: The present invention relates to: a rabies virus glycoprotein comprising an amino acid sequence represented by SEQ ID NO: 2; a recombinant vector for producing the glycoprotein; a transformant comprising the vector; and a vaccine composition comprising the rabies glycoprotein, and the like.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: July 15, 2025
    Assignees: BIOAPPLICATIONS INC., REPUBLIC OF KOREA(ANIMAL AND PLANT QUARANTINE AGENCY)
    Inventors: Yong Jik Lee, Sangmin Lee, Jae-Young Song, In-Ohk Ouh, Soo Dong Cho, Seyeon Park, Beong Sul Kang, Dong-Kun Yang, Ha-Hyun Kim
  • Patent number: 12156907
    Abstract: The present invention relates to a technique of preparing a vaccine composition from PCV2 isolated from a plant transformed with a chlorophyll-targeting recombinant vector for expression in plants and provides a recombinant vector carrying a polynucleotide coding for a recombinant protein in which a chlorophyll-targeting protein and a PCV2 capsid protein are fused to each other. In addition, provided are a transgenic plant transformed with the recombinant vector, a method for isolating and purifying a target protein from the transgenic plant, a method for preparing a vaccine composition containing virus-like particles by using same, and a vaccine composition prepared by the preparation method.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: December 3, 2024
    Assignee: BIOAPPLICATIONS INC.
    Inventors: Eun-Ju Sohn, Yongjik Lee, Sangmin Lee
  • Publication number: 20240350614
    Abstract: The present invention relates to: a recombinant vector comprising a nucleotide sequence of antigen protein(s) Lectin, CD2v, p72, p54, p30, p15, p35, E199L, and/or F317L of an African swine fever virus; a transformant transformed by means of the recombinant vector; and a vaccine composition for preventing African swine fever, comprising, as an active ingredient, African swine fever virus antigen protein(s) Lectin, CD2v, p72, p54, p30, p15, p35, E199L, and/or F317L, isolated from the transformant; and the like.
    Type: Application
    Filed: August 12, 2022
    Publication date: October 24, 2024
    Applicant: BioApplications Inc.
    Inventors: Hyangju KANG, Bo-Hwa CHOI, Eun-Ju SOHN
  • Publication number: 20240316184
    Abstract: The present invention relates to a plant-based COVID-19 variant recombinant spike protein expression vector, and a recombinant protein using the expression vector, wherein a plant expression system is used such that the recombinant protein does not have the disadvantages of animal-derived recombinant proteins and exhibits an excellent SARS coronavirus 2 prevention and treatment effect, and thus can be effectively utilized as a safe composition for preventing and treating COVID-19.
    Type: Application
    Filed: July 19, 2022
    Publication date: September 26, 2024
    Applicant: BioApplications Inc.
    Inventors: Eun-Ju SOHN, Bo-Hwa CHOI, Hyangju KANG, Kyungmin MIN, Minhee PARK, Nam Hyung KIM, Daniel KIM, Yoo-Kyoung LEE, Byung-Chul KIM, Heeji LIM, Sundong JANG, Kwangwook KIM, Soo Ji KIM, Dokeun KIM, You-Jin KIM, Jung-Ah LEE, Woo-Jung PARK
  • Patent number: 12097255
    Abstract: The present invention provides: a recombinant expression vector comprising a gene encoding a porcine parvovirus VP2 protein; a recombinant plant or a recombinant insect cell transformed with the vector; and a vaccine composition for a porcine parvovirus and a composition for diagnosing porcine parvovirus, both of which contain a porcine parvovirus VP2 protein obtained from the recombinant plant or the recombinant insect cell. When the recombinant plant or recombinant insect cell of the present invention is used, the porcine parvovirus antigenic protein can be produced with high efficiency, and the porcine parvovirus antigenic protein production method using the recombinant plant or recombinant insect cell has excellent safety and stability compared with other antigen production methods.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 24, 2024
    Assignees: REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY), BIOAPPLICATIONS INC.
    Inventors: Jae-Young Song, In-Ohk Ouh, Soodong Cho, Yongjik Lee, Ju-Yeon Lee, In-Soo Cho
  • Publication number: 20240293335
    Abstract: The present invention relates to a technology for constructing and producing, in the form of virus-like particles (VLPs), alfalfa mosaic virus (AMV) isolated from a plant transformed using a recombinant vector for plant expression that is targeted to the chloroplast, and provides a recombinant vector comprising a polynucleotide encoding a recombinant protein in which a chloroplast-targeting protein and an AMV capsid protein are fused. The present invention also provides a transgenic plant transformed by the recombinant vector, a method for isolating and purifying a target protein from the transgenic plant, a method for producing virus-like particles using same, and the like.
    Type: Application
    Filed: February 11, 2022
    Publication date: September 5, 2024
    Applicant: BioApplications Inc.
    Inventors: Youngmin PARK, Sooji SONG, Kyungmin MIN
  • Patent number: 11958883
    Abstract: The present invention provides a recombinant expression vector comprising a gene encoding canine parvovirus 2a VP2 or 2b VP2 protein, a recombinant plant into which the vector is transformed, a vaccine composition against canine parvovirus, comprising canine parvovirus 2a VP2 or 2b VP2 protein obtained from the recombinant plant, and a composition for diagnosing canine parvovirus. When the recombinant plant of the present invention is used, canine parvovirus 2a VP2 or 2b VP2 antigen protein can be rapidly produced with high efficiency. Since the composition for diagnosing canine parvovirus according to the present invention uses a recombinant antigen protein, there is no possibility of contamination due to live virus handling, and thus the composition is safe, and the presence or absence of canine parvovirus infection can be rapidly diagnosed from a large amount of samples.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 16, 2024
    Assignees: REPUBLIC OF KOREA(ANIMAL AND PLANT QUARANTINE AGENCY), BIOAPPLICATIONS INC.
    Inventors: In-Ohk Ouh, Jae-Young Song, Ju-Yeon Lee, Soo Dong Cho, Jienny Lee, Yongjik Lee
  • Patent number: 11845945
    Abstract: Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: December 19, 2023
    Assignee: BIOAPPLICATIONS INC.
    Inventors: In Hwan Hwang, Hyang Ju Kang
  • Publication number: 20230113417
    Abstract: The present invention relates to a method for mass-producing a target protein in a plant and, more specifically, to a method for producing high levels of protein in plant leaf cells, in which an expression cassette construct for high expression of a target gene and an expression cassette construct for high expression of p38 as a gene silencing suppressor, are prepared, a binary vector for transient expression in plant cells, having the construct together, is then prepared, and the binary vector is then subjected to agrobacterium-mediated transformation by using a single agrobacterium culture.
    Type: Application
    Filed: February 1, 2021
    Publication date: April 13, 2023
    Applicants: POSTECH ACADEMY-INDUSTRY FOUNDATION, BioApplications Inc.
    Inventors: In Hwan HWANG, Hyang Ju KANG, Jun Ho LEE, Shijian SONG, Selvan Thangarasu MUTHAMIL
  • Patent number: 11484589
    Abstract: Provided is a swine fever antigen fused with a porcine Fc fragment, and more particularly, to a vaccine composition having an autoimmune-enhancing effect by binding the Fc fragment to a swine fever antigen, and a preparation method thereof.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 1, 2022
    Assignees: BIOAPPLICATIONS INC., REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
    Inventors: Yongjik Lee, Dong-Jun An, Se Eun Choe, Jae-Young Song, In-Soo Cho
  • Patent number: 11434496
    Abstract: Provided is a recombinant vector including a new BiP gene fragment, and when a target protein is prepared using the recombinant vector of the subject matter, use stability can be enhanced and the production amount of target protein can also be increased by minimizing a foreign peptide sequence remaining in the target protein.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: September 6, 2022
    Assignee: BIOAPPLICATIONS INC.
    Inventor: Yongjik Lee
  • Publication number: 20220235366
    Abstract: Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.
    Type: Application
    Filed: February 14, 2022
    Publication date: July 28, 2022
    Applicant: BIOAPPLICATIONS INC.
    Inventors: In Hwan HWANG, Hyang Ju KANG
  • Patent number: 11279943
    Abstract: Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: March 22, 2022
    Assignee: BIOAPPLICATIONS INC.
    Inventors: In Hwan Hwang, Hyang Ju Kang
  • Patent number: 10947278
    Abstract: Provided is a recombinant vector including a porcine Fc fragment. By fusing the porcine Fc fragment with various target proteins by using the recombinant vector of the present invention, not only target proteins may be expressed using various hosts including plants, but the productivity and stability of target proteins may also be increased.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: March 16, 2021
    Assignee: BIOAPPLICATIONS INC.
    Inventor: Yongjik Lee
  • Patent number: 10857217
    Abstract: Provided is an antigen fused with a porcine Fc fragment, a vaccine composition having a self-adjuvanting effect by binding an Fc fragment to various antigens, and a method of producing the antigen.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: December 8, 2020
    Assignee: BIOAPPLICATIONS INC.
    Inventor: Yongjik Lee
  • Publication number: 20200354737
    Abstract: Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.
    Type: Application
    Filed: January 17, 2018
    Publication date: November 12, 2020
    Applicant: BIOAPPLICATIONS INC.
    Inventors: In Hwan HWANG, Hyang Ju KANG
  • Publication number: 20200289641
    Abstract: Provided is a swine fever antigen fused with a porcine Fc fragment, and more particularly, to a vaccine composition having an autoimmune-enhancing effect by binding the Fc fragment to a swine fever antigen, and a preparation method thereof.
    Type: Application
    Filed: September 16, 2019
    Publication date: September 17, 2020
    Applicants: BIOAPPLICATIONS INC., REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
    Inventors: Yongjik LEE, Dong-Jun AN, Se Eun CHOE, Jae-Young SONG, In-Soo CHO